Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:48 AM
Ignite Modification Date:
2025-12-24 @ 11:48 AM
NCT ID:
NCT05296161
Eligibility Criteria:
Inclusion Criteria:
* A current diagnosis of relapsing remitting multiple sclerosis according to the 2017 McDonald criteria34
* EDSS score of 0 to 6.5
* Treatment with ocrelizumab for a minimum of 48 weeks (two 300 mg infusions and one 600 mg infusion)
Exclusion Criteria:
* Previous treatment with alemtuzumab, cladribine or stem cell transplantation
* Relapse in the past 3 months prior to inclusion
* Subsequent treatment with another DMT next to ocrelizumab in the past 6 months prior to inclusion
* Inability to undergo regular MRI scanning
* Women who are pregnant or expect to become pregnant during the study period
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
60 Years
Study:
NCT05296161
Study Brief:
Protocol Section:
NCT05296161